The ADA estimates that 6.5 million of the 24 million people in the U.S. with diabetes are undiagnosed, resulting in an untreated condition that allows the disease’s medical complications to worsen.  The ADA also estimates that 57 million Americans have “pre-diabetes” – impaired fasting glycemia and/or impaired glucose tolerance – a proven precursor to diabetes.  Most of these people are unaware of their condition.   

Early detection triggers interventions that can greatly improve outcomes for diabetic individuals and delay or prevent the onset of diabetes for pre-diabetes sufferers.  In response, organizations as varied as retail pharmacies, corporate health departments, insurers, local/state/federal government(s) and advocacy groups have greatly increased their focus on early screening.  Yet, current diabetes screeners are underutilized due to the pain, mess and biohazard risk that comes from the blood draw and/or the high hassle factor and cost of glucose tolerance tests. 

Grove Instruments™'s breakthrough technology will provide a solution to these important concerns by delivering a product that eliminates the deficiencies of current technologies.

Accurate, Painless Screening
Our clinical results accurately identify if a person is at risk for diabetes and pre-diabetes or not, providing the appropriate referral for further testing that other screeners provide…without the pain and hassle of a blood draw.

Safe to Operate
No blood exposure means no biohazard risk for the screening subject or administrator.

Fast Results
The Grove Instruments™ device delivers a reading in less than 25 seconds.

Easy-to-Use
Three easy steps...that's all it takes to operate the device.

Affordable
With no supplies required, screening can be performed with no cost per test.